Risks of metabolic syndrome in the ADVANCE and NAMSAL trials

Risks of metabolic syndrome in the ADVANCE and NAMSAL trials

IntroductionThe ADVANCE and NAMSAL trials evaluating antiretroviral drugs have both reported substantial levels of clinical obesity in participants. As one of the main risk factors for metabolic syndrome, growing rates of obesity may drive metabolic syndrome development. This study aims to evaluate...

Full description

Bibliographic Details
Main Authors: Tamara Tovar Sanchez, Mireille Mpoudi-Etame, Charles Kouanfack, Eric Delaporte, Alexandra Calmy, Francois Venter, Simiso Sokhela, Bronwyn Bosch, Godspower Akpomiemie, Angela Tembo, Toby Pepperrell, Bryony Simmons, Carmen Perez Casas, Kaitlyn McCann, Manya Mirchandani, Andrew Hill
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-09-01
Series:Frontiers in Reproductive Health
Subjects:
metabolic syndrome
cardiovascular
antriretroviral medication
tenoforvir disoproxil fumarate
tenofovir alafenamide
Online Access:https://www.frontiersin.org/articles/10.3389/frph.2023.1133556/full

Internet

https://www.frontiersin.org/articles/10.3389/frph.2023.1133556/full

Similar Items